in a prospectively randomized cooperative study patients with metastatic breast cancer were treated with or without corynebacterium parvum ( c.p . ) 5 mg/sc/m2 on day 1 in addition to cao/cmf ( cyclophosphamid ( c ) 150 mg/m2/d per os x 5 d and adriamycine ( a ) 50 mg/m2 i.v . d 1 and oncovin ( o ) 1.0 mg/m2 i.v . d 1 . 6 cao-cycles q 28 days later were followed by monthly cmf cycles q 28 d with cyclophosphamide ( same dose ) , methotrexate 30 mg/m2 i.v . 1 and 5-fluorouracil 600 mg/m2 i.v . d 1 ) .
C0950521
cmf
C0016360
5-fluorouracil